XXXX and @entity632 combination in the first-line treatment of @entity0 .

@entity632 @entity1 @entity137 @entity6023 @entity0 @entity390 @entity391 @entity1311 @entity1370
Anthracyclines and @entity6023 are currently the most effective drugs in the treatment of metastatic @entity0 . The aim of this study was to determine the efficacy and @entity137 of @entity1311 and @entity632 combination in the first-line treatment of @entity0 . Forty-five @entity1 with @entity0 were recruited in the study. Median age was 49 years (range, 33-70). Treatment protocol: @entity632 (50 mg/m2/day, 30-min infusion) followed by @entity1311 (200 mg/m2/day, 3-hr infusion) every 3 weeks. Response rates included complete response in 13 (28.9%) @entity1 and partial response in 19 (42.2%) @entity1 , with an overall response rate of 71%. Five (11%) @entity1 had stable disease and 8 (18%) @entity1 had progressive disease. At a median follow-up of 19.7 months, median time to progression for all @entity1 was 19.9 months (95% confidence interval, 12.8 to 27 months). Median overall survival time was 28.4 months. Grade 3-4 @entity390 / @entity391 and hematological @entity137 were observed in 12 (26%) and 6 (13.3%) @entity1 , respectively. @entity1370 was observed in 2 (4.4%) @entity1 . In this trial, @entity1311 and @entity632 combination was demonstrated to be a favorable and active regimen in the first-line treatment of @entity0 .
